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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 301 (FGE.301): 
A sulphur substituted pyrimidin-derivative and its hydrochloride salt from 
Chemical Group 301 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate two flavouring substances, 4-amino-5,6-
dimethylthieno[2,3-d]pyrimidin-2(1H)-one [FL-no: 16.116] and 4-amino-5,6-dimethylthieno[2,3-
d]pyrimidin-2(1H)-one hydrochloride [FL-no: 16.120] in the Flavouring Group Evaluation 301, using 
the Procedure in Commission Regulation (EC) No 1565/2000. None of the substances were considered 
to have genotoxic potential. The substances were evaluated through a stepwise approach (the 
Procedure) that integrates information on structure-activity relationships, intake from current uses, 
toxicological threshold of concern, and available data on metabolism and toxicity. The Panel 
concluded that the two substances [FL-no: 16.116 and 16.120] do not give rise to safety concerns at 
their levels of dietary intake, estimated on the basis of the MSDI approach. 
© European Food Safety Authority, 2011 
SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate two flavouring substances in the 
                                                     
 
1  On request from the Commission, Question No EFSA-Q-2009-00581, adopted on 19 May 2011. 
2  Panel members Arturo Anadon, Mona-Lise Binderup, Wilfried Bursch, Laurence Castle, Riccardo Crebelli, Karl-Heinz 
Engel, Roland Franz, Nathalie Gontard, Thomas Haertle, Trine Husøy, Klaus-Dieter Jany, Catherine Leclercq, Jean Claude 
Lhuguenot, Wim Mennes, Maria Rosaria Milana, Karla Pfaff, Kettil Svensson, Fidel Toldra, Rosemary Waring, Detlef 
Wölfle. cef-unit@efsa.europa.eu   
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this Opinion: Ulla Beckman Sundh, Vibe Beltoft, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, 
Rainer Gürtler, Frances Hill, Trine Husøy, John Christian Larsen, Pia Lund, Wim Mennes, Gerard Mulder, Karin Nørby, 
Gerard Pascal, Iona Pratt, Gerrit Speijers, Harriet Wallin and EFSA’s staff member Kim Rygaard Nielsen for the preparatory 
work on this scientific Opinion. 
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Flavouring Group Evaluation 301 (FGE.301), using the Procedure as referred to in the Commission 
Regulation (EC) No 1565/2000. These two flavouring substances belong to chemical group 30, Annex 
I of the Commission Regulation (EC) No 1565/2000. 
The present Flavouring Group Evaluation deals with a sulphur substituted pyrimidin-derivative and its 
hydrochloride salt from chemical group 30. 
The two flavouring substances (candidate substances) have no possibility for geometrical or optical 
isomers. 
Both of the flavouring substances are classified into structural class III. 
Neither of the substances in the present group has been reported to occur naturally in food items. 
In its evaluation, the Panel as a default used the Maximised Survey-derived Daily Intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavouring Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
The results for the available genotoxicity studies do not raise a concern for genotoxicity and hence do 
not preclude the evaluation of the two candidate substances in this FGE through the Procedure. 
From the data available it is not possible to conclude that the two candidate substances in this group 
[FL-no: 16.116 and 16.120] would be metabolised to innocuous products at the reported levels of 
intake as flavouring substances. 
According to the default MSDI approach, the two flavouring substances in this group have a total 
intake in Europe of 610 microgram/capita/day which is above the threshold of concern value for 
structural class III of 90 microgram/person/day. However, an adequate NOAEL exists of 10 
microgram/kg bw/day from a 13-weeks study for the candidate substance 4-amino-5,6-
dimethylthieno[2,3-d]pyrimidine-2(1H)-one hydrochloride [FL-no: 16.120] which provides a margin 
of safety of 5900.  
When the estimated intakes were based on the mTAMDI approach they were 3600 and 4200 
microgram/person/day for the two flavouring substances belonging to structural class III. These 
intakes are above the threshold of concern of 90 microgram/person/day for structural class III 
substances. Therefore, for these two substances more reliable exposure data are required. On the basis 
of such additional data, these flavouring substances should be reconsidered along the steps of the 
Procedure. Following this procedure additional toxicological data might become necessary. 
In order to determine whether the conclusion for the two candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity for the materials of commerce have been provided for 
both flavouring substances.  
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The Panel concluded that the two candidate substances 4-amino-5,6-dimethylthieno[2,3-d]pyrimidin-
2(1H)-one [FL-no: 16.116] and 4-amino-5,6-dimethylthieno[2,3-d]pyrimidin-2(1H)-one hydrochloride 
[FL-no: 16.120] would present no safety concern at the estimated levels based on the MSDI approach. 
KEYWORDS 
Flavourings, pyrimidin-derivative, food, safety, FGE.301.  
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the Register prior to their authorisation and inclusion in a Union List according to 
Commission Regulation (EC) No 1565/2000 (EC, 2000a). In addition, the Commission requested 
EFSA to evaluate newly notified flavouring substances, where possible, before finalising the 
evaluation programme. 
In addition, in letter of 11 May 2009 the Commission requested EFSA to carry out a risk assessment 
on 4-amino-5,6-dimethylthieno[2,3-d]pyrimidin-2(1H)-one [FL-no: 16.116] and 4-amino-5,6-
dimethylthieno[2,3-d]pyrimidin-2(1H)-one hydrochloride [FL-no: 16.120] in accordance with 
Commission Regulation (EC) No 1565/2000 (EC, 2000a): 
“The European Commission requests the European Food Safety Authority to carry out a risk 
assessment on eighteen new flavouring substances in accordance with Commission Regulation (EC) 
No 1565/2000, if possible by the end of the authorisation programme, if not within nine months from 
the finalisation of that programme.”   
The deadline of the Terms of Reference for 4-amino-5,6-dimethylthieno[2,3-d]pyrimidin-2(1H)-one 
[FL-no: 16.116] and 4-amino-5,6-dimethylthieno[2,3-d]pyrimidin-2(1H)-one hydrochloride [FL-no: 
16.120] was negotiated to 31 May 2011. 
The remaining substances of this request were evaluated in other FGEs. 
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 301 
1.1. Description 
The present Flavouring Group Evaluation 301 (FGE.301), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) (The Procedure - shown in schematic form 
in Annex I of this FGE), deals with a sulphur substituted pyrimidin-derivative and its hydrochloride 
salt from chemical group 30, Annex I of Commission Regulation (EC) No 1565/2000 (EC, 2000a). 
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The flavouring substances under consideration, as well as the chemical Register names, FLAVIS- (FL-
), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract 
Manufactures Association- (FEMA-) numbers, structure and specifications, are listed in Table 1. 
The two flavouring substances (candidate substances) are 4-amino-5,6-dimethylthieno[2,3-
d]pyrimidin-2(1H)-one [FL-no: 16.116] and 4-amino-5,6-dimethylthieno[2,3-d]pyrimidin-2(1H)-one 
hydrochloride [FL-no: 16.120]. No sufficiently structurally related substances to support the 
evaluation of the candidate substances were identified. 
The outcome of the Safety Evaluation is summarised in Table 2a. 
1.2. Stereoisomers 
The two candidate substances cannot exist as geometrical or optical isomers. 
1.3. Natural Occurrence in Food 
The candidate substances [FL-no: 16.116 and 16.120] have not been reported to occur naturally in any 
food items (TNO, 2010). 
2. Specifications 
Purity criteria for the two substances have been provided by the Flavour Industry (Flavour Industry, 
2009l) (Table 1). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000a), this information is adequate for both candidate substances.  
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
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assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 
the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 
in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
The anticipated annual volume of production of 4-amino-5,6-dimethylthieno[2,3-d]pyrimidin-2(1H)-
one [FL-no: 16.116] and its hydrochloride salt [FL-no: 16.120] from use as flavouring substances in 
Europe has been reported to be approximately 5000 kg (Flavour Industry, 2009l). 
The annual production volume is given as a total for the two flavouring substances rather than 
individual values. Based on this production volume the daily per capita intake is calculated to 610 µg 
in total (Table 2). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the two candidate substances information on food categories and normal and maximum use 
levels5,6 were submitted by the Flavour Industry (Flavour Industry, 2009l). The two candidate 
substances are used in flavoured food products divided into the food categories, outlined in Annex III 
of the Commission Regulation (EC) No 1565/2000 (EC, 2000a), as shown in Table 3.1. For the 
present calculation of mTAMDI, the reported normal use levels were used. In the case where different 
use levels were reported for different food categories the highest reported normal use level was used. 
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are 
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No 
production data are available for the enlarged EU. 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile 
of reported usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from 
figures derived from 12 model flavouring substances (EFFA, 2004e). 
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Table 3.1 Use of Candidate Substances 
Food 
category 
Description Flavourings used 
01.0 Dairy products, excluding products of category 2 Yes 
02.0 Fats and oils, and fat emulsions (type water-in-oil) No 
03.0 Edible ices, including sherbet and sorbet Yes 
04.1 Processed fruits No 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and 
legumes), and nuts & seeds 
No 
05.0 Confectionery Yes 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses 
& legumes, excluding bakery 
Yes 
07.0 Bakery wares Yes 
08.0 Meat and meat products, including poultry and game No 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  No 
10.0 Eggs and egg products No 
11.0 Sweeteners, including honey No 
12.0 Salts, spices, soups, sauces, salads, protein products etc. No 
13.0 Foodstuffs intended for particular nutritional uses Yes 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products Yes 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts Yes 
15.0 Ready-to-eat savouries No 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not 
be placed in categories 1 – 15 
Yes 
 
According to the Flavour Industry the normal use levels for the candidate substances are in the range 
of 4  - 10 mg/kg food and the maximum use levels are in the range of 8.5 - 25 mg/kg (Flavour 
Industry, 2009l). 
The mTAMDI values for the two candidate substances are 3600 and 4200 microgram/person/day for 
[FL-no: 16.116 and 16.120], respectively.  
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II. 
4. Absorption, Distribution, Metabolism and Elimination 
There are structural similarities between the candidate substances and the DNA bases cytosine and 
guanine which may indicate that oxidation of the amino group and eventually ring opening occur in 
this part of the molecule. However, there is no experimental evidence of the metabolism of the 
thiophene moiety of the molecule, and therefore the candidate substances cannot be anticipated to be 
metabolised to innocuous products in accordance with the decision for other thiophenes evaluated in 
FGE.21. 
Because both candidate substances have the same pharmacokinetics after oral administration, leading 
to the same Cmax, the systemic toxicity of the two substances will be similar. 
For more detailed information, see Annex III. 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
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In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
For the safety evaluation of the two candidate substances from chemical group 30 the Procedure as 
outlined in Annex I was applied, based on the MSDI approach. The stepwise evaluations of the 
substances are summarised in Table 2. 
Step 1 
Both candidate substances are classified according to the decision tree approach by Cramer et al. 
(Cramer et al., 1978) into structural class III. 
Step 2 
Step 2 requires consideration of the metabolism of the candidate substances. The two candidate 
substances [FL-no: 16.116 and 16.120], cannot be anticipated to be metabolised to innocuous products 
and thus the evaluation proceeds via the B-side of the Procedure scheme. 
Step B3 
The total estimated daily per capita intake of the two candidate substances [FL-no: 16.116 and 16.120] 
is 610 microgram, which is above the threshold for their structural class of 90 microgram/person/day 
(class III).  
The Panel therefore considered a 13-week oral sub-chronic toxicity study carried out using the 
candidate substance 4-amino-5,6-dimethylthieno[2,3-d]pyrimidin-2(1H)-one hydrochloride [FL-no: 
16.120] in rats (see Section 8.2). Based on this study, a No Observed Adverse Effect Level (NOAEL) 
of 60 mg/kg body weight (bw)/day was identified. The MSDI value of 610 microgram/capita/day is 
equivalent to 10.2 microgram/kg bw/day, at a body weight of 60 kg. Thus, the margin of safety is 
5900.  
Based on results of the safety evaluation sequence of the Procedure, 4-amino-5,6-dimethylthioeno[2,3-
d]pyrimidin-2(1H)-one [FL-no: 16.116] and its hydrochloride salt [FL-no: 16.120] are not anticipated 
to pose a safety concern when used as flavouring substances at the estimated levels of intake, based on 
the MSDI approach. 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The estimated intakes of the substances [FL-no: 16.116 and 16.120] assigned to structural class III, 
based on the mTAMDI, are 3600 and 4200 microgram/person/day, respectively, which are above the 
threshold of concern for structural class III of 90 microgram/person/day. 
Thus, for the two candidate substances [FL-no: 16.116 and 16.120] further information is required. 
This would include more reliable intake data and then, if required, additional toxicological data. 
For comparison of the MSDI and mTAMDI values, see Table 6.1. 
 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI* 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
16.116 4-Amino-5,6-dimethylthioenol[2,3-
d]pyrimidin-2(1H)-one 
0.0 3600 Class III 90 
16.120 4-Amino-5,6-dimethylthioenol[2,3-
d]pyrimidin-2(1H)-one hydrochloride 
610 4200 Class III 90 
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* Industry has provided a total production volume for 16.116 and 16.120 of 5000 kg/year, MSDI covers both substances, meaning that the value may range from 
0 to 610 μg/capita/day for each of the two substances. 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
On the basis of the reported annual production volumes in Europe (Flavour Industry, 2009l), the 
combined estimated daily per capita intake as flavourings of the two candidate substances belonging 
to structural class III is 610 microgram. This value exceeds the threshold of concern for structural class 
III of 90 microgram/person/day. However, as there is an appropriate NOAEL from an adequate 13-
week study on the candidate substance [FL-no: 16.120], no safety concern would be anticipated for 
these flavouring compounds at the anticipated level of use as a flavouring substance. No structurally 
related supporting substances have been identified that should be taken into account for the combined 
intake calculation.  
8. Toxicity 
8.1. Acute Toxicity 
A study is available for one of the candidate substances. Based on clinical observations and gross 
necropsy, 4-amino-5,6-dimethylthieno[2,3-d]pyrimidin-2(1H)-one [FL-no: 16.116] did not show any 
evidence of toxicity when administered orally to rats at dose levels up to 50 mg/kg bw (Arulnesan, 
2007). 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Subacute and subchronic toxicity data are available for the two candidate substances, 4-amino-5,6-
dimethylthieno[2,3-d]pyrimidin-2(1H)-one [FL-no: 16.116] and 4-amino-5,6-dimethylthieno[2,3-
d]pyrimidin-2(1H)-one hydrochloride [FL-no: 16.120]. 
A 21-day oral toxicity screen test was carried out using the candidate substance [FL-no: 16.116] in 
Sprague Dawley Crl:CD® (SD) rats (5/sex/group) at doses that were calculated to be 10.3, 29.4 and 
101.0 mg/kg/day for males and 10.9, 31.1 and 103.0 mg/kg/day for females (Ross, 2008). There were 
no clinical signs that were attributable to treatment and no animals were killed prematurely. No effect 
of treatment upon body weight gain or food consumption was observed. Liver weights were slightly 
higher in males and females receiving 100 mg/kg/day. There were no treatment-related macroscopic or 
microscopic changes in the intact animals or in any of the tissues examined. 
A 13-week oral sub-chronic toxicity study was carried out using the candidate substance 4-amino-5,6-
dimethylthieno[2,3-d]pyrimidin-2(1H)-one hydrochloride [FL-no: 16.120] in Sprague Dawley 
Crl:CD® (SD) rats (20/sex/group) by dietary ingestion resulting in doses of 10.3, 30.8 and 61.9 mg/kg 
bw/day for males and 10.3, 30.6 and 60.3 mg/kg body weight (bw)/day for females (Ross, 2009). The 
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test material induced no treatment-related changes in mortality, appearance, behavior, body weight, 
food consumption or ophthalmic function.  
Although some changes were reported in certain hematological parameters, they were inconsistent, 
and minor, either occurred in one sex only or lacked a dose relationship and therefore were not 
considered toxicologically significant.  Clinical chemistry revealed statistically significantly increased 
total plasma cholesterol concentrations in low-dose females on day 14 (+29 %) and week 13 (+25 %) 
and in mid- (30 mg/kg bw/day) and high-dose females on day 14 (+23 % and +46 %, respectively), 
week 6 (+28 % and +44 %, respectively) and week 13 (+34 % and +49 %, respectively) compared to 
the control group. In males, a significant increase in total plasma cholesterol concentration was 
reported at the high-dose level, but only on day 14 (+25 %). Total triglyceride concentration were 
slightly but statistically significantly increased in high dose males (+59 %), but only at day 14, and in 
high dose females at week 13 (+50 %). The increased total plasma cholesterol and triglyceride levels 
were considered to be associated with increased liver weights (liver weights of females: control: 
10.833 g (mean of 20 rats); low-dose: 11.099 g; mid-dose: 11.819 g; high-dose: 11.855 g. Liver 
weights of male: control: 20.154 g; low-dose: 20.637 g; mid-dose: 22.053 g; high-dose: 23.095 g). No 
other dose related changes were noted in clinical chemistry parameters.   
Urinalysis revealed a dose-dependent increase in protein excretion attaining statistical significance in 
males and a non-dose-dependent reduction in specific gravity at all dose levels in females. The 
increase in urinary protein levels in males was attributed to high values in a single animal.  
After 13 weeks of treatment, relative liver weights were elevated in a dose-related manner in animals 
given 30 or 60 mg/kg/day, relative kidney weights were slightly high in males given 60 mg/kg/day 
and relative thyroid weights were slightly high in females given 60 mg/kg/day. There were no 
treatment-related macroscopic changes after 13 weeks of treatment. Histopathological changes related 
to treatment with [FL-no: 16.120] were confined to minimal centrilobular hypertrophy in the liver of a 
few animals given 60 mg/kg/day. There was no evidence of hepatocyte vacuolation, indicative of 
disturbances in intra-hepatocyte fat metabolism associated with the changes in plasma total cholesterol 
and triglycerides found in clinical chemistry. 
The Panel noted that histopathological changes were confined to minimal centrilobular hypertrophy in 
the liver of a few animals at the top dose. The Panel considered that these changes were adaptive in 
nature, and that the increases in plasma total cholesterol in female animals at all doses and in males 
receiving 60 mg/kg bw/day, also the increases in plasma total triglycerides in both males and females 
receiving 60 mg/kg bw/day, were associated with the adaptive changes. The Panel considered 
therefore that these clinical chemistry changes were not of toxicological concern, and that since the 
changes in liver weight were not accompanied by any significant histopathological change, the top 
dose of 60 mg/kg bw/day could be considered as a NOAEL, as proposed by the authors of the study 
(Ross, 2009).  
Because both candidate substances have the same pharmacokinetics after oral administration, leading 
to the same Cmax the systemic toxicity of the two substances will be similar. Therefore the 13-weeks 
study for [FL-no: 16.120] is also valid for [FL-no: 16.116]. 
Repeated dose toxicity data are summarised in Annex IV, Table IV.2. 
8.3. Developmental / Reproductive Toxicity Studies 
No data are submitted or available from literature search. 
8.4. Genotoxicity Studies 
A reverse mutation assay was carried out on the candidate substance 4-amino-5,6-dimethylthieno[2,3-
d]pyrimidine-2(1H)-one hydrochloride [FL-no: 16.120] in Salmonella typhimurium strains TA98, 
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TA100, TA1535 and TA1537 and in Escherichia coli strain WP2 uvrA in the presence and absence of 
S9 and in accordance with the OECD Guideline 4717 (Zhang, 2008a). It was concluded that 4-amino-
5,6-dimethylthieno[2,3-d]pyrimidine-2(1H)-one hydrochloride [FL-no: 16.120] was not mutagenic to 
S. typhimurium strains TA98, TA100, TA1535 and TA1537 and to E. coli strain WP2 uvrA under the 
test conditions. 
An in vitro chromosome aberration test was performed on 4-amino-5,6-dimethylthieno[2,3-
d]pyrimidine-2(1H)-one hydrochloride [FL-no: 16.120] in the presence and absence of S9 according 
to OECD Guideline 4738 (Zhang, 2008c).Chromosome aberrations were not observed in the solvent 
control cultures and only sporadically encountered in the cultures treated with the test material. The 
percentage of cells with chromosome abnormalities was at a level similar to the historical solvent 
control data from this laboratory (1-4 %) and did not meet the criteria for a positive response. It is 
concluded that 4-amino-5,6-dimethylthieno[2,3-d]pyrimidine-2(1H)-one hydrochloride [FL-no: 
16.120] did not induce chromosomal aberrations in cultured WBL Chinese hamster ovary cells under 
the conditions of the test. 
A mouse micronucleus test was performed on 4-amino-5,6-dimethylthieno[2,3-d]pyrimidine-2(1H)-
one hydrochloride [FL-no: 16.120] in accordance with the OECD Guideline 4749 (Zhang, 2008b). 
Five groups of 14 male mice received the test material by gavage, suspended in 0.5 % methyl cellulose 
in water at dose levels of 500, 1000 and 2000 mg/kg. A negative control group and a positive control 
group (cyclophosphamide at 70 mg/kg) were included. 
Seven animals from each group were sacrificed at 24 hours and seven were sacrificed at 48 hours after 
dosing. 2000 polychromatic erythrocytes (PCEs) per animal were scored for presence of micronuclei. 
In addition, the numbers of normochromatic erythrocytes with micronuclei per 2000 polychromatic 
erythrocytes were scored and the polychromatic/normochromatic ratio was established. The 
presence/absence of micronuclei was also confirmed by applying a DNA specific stain (Feulgen stain) 
to slides from the positive control group, and to the high dose group at 24 hours. There was no 
statistically significant or dose dependent increase in the number of PCEs with micronuclei at any of 
the dose levels or time points compared to the negative control group. 
Based on the results above, it was concluded that the test material did not induce micronuclei in this 
test at the dose levels up to 2000 mg/kg administered orally by gavage. There was no reduction in the 
ratio of normochromatic to polychromatic erythrocytes and therefore it is not possible to conclude that 
the test compound reaches the bone marrow. However, as the substance did not raise a concern for 
chromosomal damage in the in vitro assay, this limitation would not put a constraint on the evaluation 
of the substance.  
The in vitro and in vivo genotoxicity studies on the candidate substance [FL-no: 16.120] have been 
carried out to OECD Guidelines and are of good quality and are considered to be supporting for the 
candidate substance [FL-no: 16.116]. Negative results were obtained in all of the genotoxicity studies 
carried out on the candidate substance [FL-no: 16.120]. 
Genotoxicity data are summarised in Annex IV, Table IV.4 and Table IV.5. 
9. Conclusions 
The two candidate substances are a sulphur-substituted pyrimidine derivative [FL-no: 16.116] and its 
hydrochloride salt [FL-no: 16.120] that belong to EU chemical group 30. 
                                                     
 
7 OECD Guideline for Testing of Chemicals – 471, Bacterial Reverse Mutation Test” (OECD, 1997). 
8 OECD Guideline for the Testing of Chemicals – 473, In Vitro Mammalian Chromosome Aberration Test 
(1997). 
9 OECD Guideline for the Testing of Chemicals, Section 474 (OECD, 1997). 
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The two candidate substances cannot exist as geometrical or optical isomers. 
Both of the flavouring substances are classified into structural class III. 
Neither of the substances in the present group has been reported to occur naturally in any food items. 
The results for the available genotoxicity studies do not raise a concern for genotoxicity and hence do 
not preclude the evaluation of the two candidate substances in this FGE through the Procedure. 
From the data available it is not possible to conclude that the two candidate substances in this group 
[FL-no: 16.116 and 16.120] would be metabolised to innocuous products at the reported levels of 
intake as flavouring substances. 
According to the default MSDI approach, the two flavouring substances in this group have a total 
intake in Europe of 610 microgram/capita/day which is above the threshold of concern value for 
structural class III of 90 microgram/person/day. However, a NOAEL of 60 mg/kg bw/day could be 
derived from a 13-weeks study for the candidate substance 4-amino-5,6-dimethylthieno[2,3-
d]pyrimidine-2(1H)-one hydrochloride [FL-no: 16.120] which provides a margin of safety of 5900.  
When the estimated intakes were based on the mTAMDI approach they were 3600 and 4200 
microgram/person/day for the two flavouring substances belonging to structural class III. These 
intakes are above the threshold of concern of 90 microgram/person/day for structural class III 
substances. Therefore, for these two substances more reliable exposure data are required. On the basis 
of such additional data, these flavouring substances should be reconsidered along the steps of the 
Procedure. Following this procedure additional toxicological data might become necessary. 
In order to determine whether the conclusion for the two candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity for the materials of commerce have been provided for 
both flavouring substances. 
The Panel concluded that the two candidate substances 4-amino-5,6-dimethylthieno[2,3-d]pyrimidin-
2(1H)-one [FL-no: 16.116] and 4-amino-5,6-dimethylthieno[2,3-d]pyrimidin-2(1H)-one hydrochloride 
[FL-no: 16.120] would present no safety concern at the estimated levels based on the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 301 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 301 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
16.116 
 
4-Amino-5,6-dimethylthioenol[2,3-
d]pyrimidin-2(1H)-one 
N
H
N SO
NH2
4669 
 
121746-18-7 
Solid 
C8H9N3OS 
195.20 
Slightly soluble 
Soluble 
 
Decompose 
IR NMR MS 
98 % 
n.a. 
n.a. 
 
 
16.120 
 
4-Amino-5,6-dimethylthioenol[2,3-
d]pyrimidin-2(1H)-one hydrochloride 
N
H
N SO
NH2 ,HCl
4669 
 
1033366-59-
4 
Solid 
C8H9N3OS,HCl 
231.70 
Sparingly soluble 
Soluble 
 
Decompose 
IR NMR MS 
99 % 
n.a. 
n.a. 
 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
n.a.: not applicable. 
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TABLE 2: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) (μg/capita/day) Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
16.116 
 
4-Amino-5,6-
dimethylthioenol[2,3-
d]pyrimidin-2(1H)-one N
H
N SO
NH2
0.0 
 
Class III 
B3: Intake above threshold, 
Data available 
Adequate NOAEL exists 
4) 6)  
16.120 
 
4-Amino-5,6-
dimethylthioenol[2,3-
d]pyrimidin-2(1H)-one 
hydrochloride 
N
H
N SO
NH2 ,HCl
610 
 
Class III 
B3: Intake above threshold, 
Data available 
Adequate NOAEL exists 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products10 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous11 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
 
10 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997a). 
 
11 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
Flavouring Group Evaluation 301
 
 
18 EFSA Journal 2011; 9(6):1994  
ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry for the two candidate substances in the 
present flavouring group (Table II.1.2). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.301 (Flavour 
Industry, 2009l) 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
16.116 6,4 
13 
- 
- 
6,4 
13 
- 
- 
- 
- 
8,5 
21 
8,5 
17 
4 
8,5 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
8,5 
17 
6,4 
13 
6,4 
13 
- 
- 
6,4 
13 
16.120 7,5 
15 
- 
- 
7,5 
15 
- 
- 
- 
- 
10 
25 
10 
20 
5 
10 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
10 
20 
7,5 
15 
7,5 
15 
- 
- 
7,5 
15 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 
multiplied by the reported use levels in the different food categories and summed up.  
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Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 
(EC, 2000a) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be Food   
Flavouring Group Evaluation 301
 
 
20 EFSA Journal 2011; 9(6):1994  
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
placed in categories 01.0 - 15.0 
 
The mTAMDI values (see Table II.2.3) are presented for each of the two flavouring substances in the present 
flavouring group, for which Industry has provided use and use levels (Flavour Industry, 2009l). The 
mTAMDI values are only given for the highest reported normal use levels. 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
16.116 4-Amino-5,6-dimethylthioenol[2,3-d]pyrimidin-2(1H)-one 3600 Class III 90 
16.120 4-Amino-5,6-dimethylthioenol[2,3-d]pyrimidin-2(1H)-one 
hydrochloride 
4200 Class III 90 
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ANNEX III: METABOLISM 
III.1. Introduction 
The present FGE consists of two candidate substances, 4-amino-5,6-dimethylthieno[2,3-d]pyrimidin-2(1H)-
one [FL-no: 16.116] and its hydrochloride salt [FL-no: 16.120]. 
III.2. Absorption, Distribution and Elimination 
One study describing the absorption and elimination of the two candidate substances from the blood was 
published. This study was performed largely to ensure that studies carried out on 4-amino-5,6-
dimethylthieno[2,3-d]pyrimidine-2(1H)-one hydrochloride [FL-no: 16.120] would be applicable to the free 
base [FL-no: 16.116] and vice versa (Taylor, 2008).  
The test was carried out following single gavage administration of the hydrochloride salt and of the free base 
to Sprague-Dawley rats (6/sex/group) at a dose level of 100 mg/kg. Blood samples were taken from the 
orbital sinus of the test animals at 0, 30 minutes, 1, 2, 4, 8 24 and 48 hours after dosing. 
Both the hydrochloride salt and the free base were identified in the plasma as the free base. Both were 
readily absorbed after oral administration in Sprague-Dawley rats. The maximum concentration (Cmax) values 
after dosing with both test materials were comparable (25056.3 ng/mL for the free base and 28600.3 ng/mL 
for the hydrochloride salt). The rate of absorption (Ka) was slightly higher for the hydrochloride salt (0.821 
hr−1) as compared to the free base (0.550 hr−1), resulting in a shorter time to reach maximum concentration 
(Tmax) and a shorter half-life of absorption phase values (i.e. 2.0 and 0.844 hours after dosing with the 
hydrochloride salt; 4.0 and 1.26 hours after dosing with the free base, respectively). The relative 
bioavailability of the free base as compared to the hydrochloride salt was 109.4 % and the mean residence 
time (MRT) in plasma after dosing with the free base (5.4 hours) was slightly higher than the MRT after 
dosing with the hydrochloride salt (4.6 hours).  
The elimination phase after dosing with both test materials appeared to follow first-order kinetics. The rates 
of elimination were slower than the rates of absorption. A slightly higher Ka and lower T1/2(e) were observed 
after administration of the free base (0.098 hr−1; 7.04 hr) than after administration of the hydrochloride salt 
(0.065 hr−1; 10.67 hr). However, the apparent clearance (CL/F) after dosing with the hydrochloride salt 
(479.39 mL/hr/kg) was slightly higher than that after dosing with the free base (438.29 mL/hr/kg), 
correlating to the small increase in relative bioavailability of the free base. The potential for accumulation in 
plasma with repeated dosing could not be assessed. Overall, the absorption and elimination kinetics for both 
test materials were comparable.  
Absorption and elimination kinetics for both test articles (4-amino-5,6-dimethylthieno[2,3-d]pyrimidine-
2(1H)-one hydrochloride [FL-no: 16.120] and 4-amino-5,6-dimethylthieno[2,3-d]pyrimidine-2(1H)-one [FL-
no: 16.116] were comparable, with the hydrochloride salt showing slightly increased rates of both absorption 
and clearance producing a shorter disposition phase compared to that observed for the free base. As a result, 
a small increase in the extent of exposure to the free base in comparison to the hydrochloride salt was 
observed. 
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III.3. Metabolism 
No studies have been undertaken specifically to examine the metabolism of the two candidate substances. 
Whilst the candidate substances have structural similarities to the DNA bases cytosine and guanine, they also 
contain a thiophene ring.  
Cytosine is degraded through the pyrimidine degradation pathway involving transformation into uracil and 
dihydrouracil through oxidation of the amino group and finally ring opening to form beta alanine (Blakely, 
1988). Guanine presents a similar structure in which the pyrimidine ring is fused with another heterocyclic 
moiety. Guanine is degraded through the purine degradation pathway involving transformation into xanthine 
and then uric acid (Voet and Voet, 1995d). 
The thiophene moiety itself may undergo S-oxidation to give a sulphoxide as primary metabolite. This can 
subsequently undergo spontaneous conjugation with glutathione (GSH). It may also exhibit reactivity toward 
protein thiols (EFSA, 2009u). Other substances containing a thiophene ring were evaluated in FGE.21 where 
it could not be concluded that the substances would be metabolised to innocuous products, and they were 
therefore taken via the B-side of the Procedure. Therefore, the two substances considered in this FGE will 
also be evaluated through the Procedure scheme via the B-side. 
III.4. Summary and Conclusions 
There are structural similarities between the candidate substances and the DNA bases cytosine and guanine 
which may indicate that oxidation of the amino group and eventually ring opening occur in this part of the 
molecule. However, there is no experimental evidence of the metabolism of the thiophene moiety of the 
molecule, and therefore the candidate substances cannot be anticipated to be metabolised to innocuous 
products in accordance with the decision for other thiophenes evaluated in FGE.21. 
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ANNEX IV: TOXICITY 
 
TABLE IV.1: ACUTE TOXICITY 
Oral acute toxicity data are available for one candidate substances of the present Flavouring Group Evaluation 
TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
4-Amino-5,6-dimethylthioenol[2,3-d]pyrimidin-2(1H)-one 
[16.116] 
Rats M Gavage No LD50 obtained (Arulnesan, 2007) Substance tested up to 50 mg/kg 
without any effect. 
 
M = Male. 
      
 
 
Subacute / Subchronic / Chronic / Carcinogenic toxicity data are available for the two candidate substances of the present Flavouring Group Evaluation from 
chemical group 30.  
TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
4-Amino-5,6-dimethylthioenol[2,3-
d]pyrimidin-2(1H)-one 
hydrochloride [16.120] 
Rats; M, F 
20 
Feeding M: 10.3, 30.8, 
61.9 mg/kg/day 
F: 10.3, 30.6, 60.3 
mg/kg/day 
13 weeks 60 (Ross, 2009) Good quality, guideline study. 
4-Amino-5,6-dimethylthioenol[2,3-
d]pyrimidin-2(1H)-one 
[16.116] 
Rats; M, F 
5 
Feeding M: 10.3, 29.4, 
101 mg/kg/day 
F: 10.9, 31.1, 103 
mg/kg/day 
21 days >100 (Ross, 2008) Good quality, guideline study. 
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TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
No developmental and reproductive toxicity data are available for the candidate substances of the present Flavouring Group Evaluation from chemical group 
30. 
 
In vitro mutagenicity/genotoxicity data are available for one candidate substance of the present Flavouring Group Evaluation from chemical group 30. 
TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
4-Amino-5,6-dimethylthioenol[2,3-
d]pyrimidin-2(1H)-one 
hydrochloride [16.120] 
Ames test S. typhimurium 
TA98; TA100; TA1535; TA1537 
0, 0.021, 0.062, 0.19, 0.56, 
1.67, 5 mg/plate 
Negative1 (Zhang, 2008a) Valid. 
Ames test E.coli WP2 uvrA 0, 0.021, 0.062, 0.19, 0.56,1.67, 
5 mg/plate 
Negative1 (Zhang, 2008a) Valid. 
Chromosomal aberration Chinese hamster ovary cells 0, 0.18, 0.55, 1.67 mg/ml Negative1 (Zhang, 2008c) Valid. 
1 With and without metabolic activation 
 
 
In vivo mutagenicity/genotoxicity data are available for one candidate substance of the present Flavouring Group Evaluation from chemical group 30.  
TABLE IV.5: GENOTOXICITY (IN VIVO) 
Chemical Name [FL-no] Test system Test Object 
 
Dose Result Reference Comments 
4-Amino-5,6-dimethylthioenol[2,3-
d]pyrimidin-2(1H)-one hydrochloride 
[16.120] 
Micronucleus test Mouse bone marrow 
cells 
500, 1000, 2000 mg/kg Negative (Zhang, 2008b) Valid. 
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ABBREVIATIONS 
ADI  Acceptable Daily Intake 
BW  Body weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CL Clearance 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GSH  Glutathione 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
Ka   Rate of absorption  
LD50  Lethal Dose, 50 %; Median lethal dose 
MRT  Mean residence time  
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PCE  Polychromatic erythrocytes 
SCE  Sister Chromatid Exchange 
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SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation 
 
